RankAlpha logo
Back to Rankings

IBIO

iBioA
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
View Chart
Current thesis
The company has transitioned into clinical development, advanced IBIO-600 toward multiple-ascending-dose testing, progressed IBIO-610 and IBIO-800 toward IND-enabling work, and reports approximately $88 million of cash and investments with runway into fiscal 2028 [#SEC-8K-2026-08-28].
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite.
What can break
FY2026 revenue was only approximately $0.1 million and the company remains loss-making.
Momentum
96
Value
59
Sentiment
69
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $1.35 · Bull $2.10 · Bear $0.75Analysis 2026-09-09; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-28 • Vendor: Data Vendor v1
Scores
As of 2026-09-09 • Model: HYBRID_IC_RP
AI Memo
As of 2026-09-09 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-09-09

Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-09. Definitions

Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $5.53
Why
Momentum96 · Δ7d -
Value59 · Δ7d 0.0
Sentiment69 · Δ7d -
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.

Confirming evidence

  • • Sentiment remains the lead driver in the composite.

Contradictions & invalidation

  • • FY2026 revenue was only approximately $0.1 million and the company remains loss-making.
  • • IBIO-600 clinical safety, tolerability, pharmacokinetic, and efficacy outcomes remain uncertain as the program moves into multiple-ascending-dose testing.
  • • The business remains pre-revenue and reported a $33.0 million FY2026 net loss, with R&D expense increasing to $19.6 million.

Catalyst clock

2026-08-28

FY2026 earnings and clinical-stage transition

Lead driver: Sentiment · See AI snapshot
Momentum
96
9% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
59
28% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
-0.0
Sentiment
69
62% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade

Composite grade A. Momentum 95.6 / Value 58.9 / Sentiment 69.4

Scenario snapshot

Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-09-09. Scenario method

B+
Bull case
20%
Probability
Target price
$2.10
Analysis reference price unavailable
Analysis 2026-09-09 · RankAlpha Sentiment Codex
Most likely
B
Base case
50%
Probability
Target price
$1.35
Analysis reference price unavailable
Analysis 2026-09-09 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$0.75
Analysis reference price unavailable
Analysis 2026-09-09 · RankAlpha Sentiment Codex
Fundamentals (TTM)
As of 2026-08-28
Market Cap
$72.03M
Beta
1.26
Shares Out
49.68M
P/E (TTM) · Derived
-4.6
P/S (TTM)
84.55
P/FCF (TTM) · Derived
-2.91
Rev YoY
-100.0%
EPS YoY
-86.9%
Gross Margin
-255.0%
Op Margin
-4089.4%
Net Debt
-$5.07M
Current Ratio
11.88
As of 2026-09-09 • Updated nightlySource: Internal modelMethods & Data